AiCuris - About the company
AiCuris is an acquired company based in Wuppertal (Germany), founded in 2006. It operates as a Developer of antiviral and antibacterial therapeutics for infectious diseases. AiCuris has raised $74.8M in funding. The company has 300 active competitors, including 75 funded and 75 that have exited. Its top competitors include companies like Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma.
Company Details
Developer of antiviral and antibacterial therapeutics for infectious diseases. The pipeline includes the development of AIC246 (Prevymis) for treating human cytomegalovirus (quinazoline-based inhibitor of the cytomegalovirus (CMV) terminase protein), AIC316 (phase II) for the treatment Herpes simplex, and AIC649 (Phase I) for Hepatitis B virus.
- Website
- www.aicuris.com/
- Registered Address
- Friedrich-Ebert-Straße 475 42117 Wuppertal
Key Metrics
Founded Year
2006
Location
Wuppertal, Germany
Stage
Acquired
Total Funding
$74.8M in 4 rounds
Latest Funding Round
Ranked
39th among 300 active competitors
Annual Revenue
€50M - €100M as on Dec 31, 2018
Employee Count
75 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Asahi Kasei (Feb 26, 2026)
Legal entities associated with AiCuris
AiCuris is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Aicuris Anti-infective Cures Gmbh CIN: HRA22253 , Germany, Active | Dec 18, 2014 | €50M - €100M (As on Dec 31, 2018) | 61 (As on Dec 31, 2020) |
AiCuris's acquisition details
AiCuris got acquired by Asahi Kasei on Feb 26, 2026 at an acquisition amount of $*****.
Click here to take a look at AiCuris's acquisition in detail
Sign up to download AiCuris' company profile
AiCuris's funding and investors
AiCuris has raised a total funding of $74.8M over 4 rounds. Its first funding round was on Apr 14, 2010.
Here is the list of recent funding rounds of AiCuris:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 01, 2017 | 2541507 | Grant (prize money) | 9692531 | 4359083 | 1980879 | 8897580 |
Jan 01, 2017 | 3935919 | Grant (prize money) | 1031827 | 3052611 | 2475383 | 4422276 |
Mar 01, 2015 | 2762165 | Grant (prize money) | 5706778 | 5106668 | 6143684 | 1176652 |
View details of AiCuris's funding rounds and investors
AiCuris' founders and board of directors
Founder? Claim ProfileAiCuris' employee count trend
AiCuris has 75 employees as of Sep 26. Here is AiCuris's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
AiCuris's Competitors and alternates
Top competitors of AiCuris include Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma. Here is the list of Top 10 competitors of AiCuris, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Tonix Pharma 2007, New York City (United States), Public | Developer of next-generation medicines for CNS and immunological disorders | $4.45M | 67/100 | |
2nd | HOOKIPA Pharma 2011, Vienna (Austria), Public | Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 65/100 | |
3rd | Ascletis Pharma 2011, Hangzhou (China), Public | Developer of small molecules for the treatment of multiple diseases | $255M | 64/100 | |
4th | Vaxart 2004, San Francisco (United States), Public | Developer of therapeutic solutions for treating multiple infectious diseases | $58M | 64/100 | |
5th | eradivir 2020, West Lafayette (United States), Series A | Developer of immunotherapies for the treatment of infectious diseases | $20.4M | 62/100 | |
6th | VBI Vaccines 2001, Cambridge (United States), Public | Developer of vaccines for the treatment of infectious diseases | $65.1M | 61/100 | |
7th | Ocugen 2013, Aurora (United States), Public | Developer of therapeutic solutions to treat various eye disorders | - | 61/100 | |
8th | SAB Biotherapeutics 2014, Sioux Falls (United States), Public | Developer of immunotherapeutics to treat infectious and autoimmune diseases | $49M | 61/100 | |
9th | Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 60/100 | |
10th | Leyden Labs 2020, Leiden (Netherlands), Series B | Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa | $303M | 59/100 | |
39th | Developer of antiviral and antibacterial therapeutics for infectious diseases | $74.8M | - | 51/100 |
Looking for more details on AiCuris's competitors? Click here to see the top ones
AiCuris's Investments and acquisitions
AiCuris has made no investments or acquisitions yet.
Reports related to AiCuris
Here is the latest report on AiCuris's sector:
News related to AiCuris
Media has covered AiCuris for a total of 15 events in the last 1 year, 5 of them have been about company updates.
•
Asahi Kasei Completes Acquisition of AicurisContract Pharma•Apr 20, 2026•Asahi Kasei, AiCuris, http://asahikasei.com
•
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents Phase 3 Data at ESCMID 2026GlobeNewswire•Apr 16, 2026•AiCuris, Asahi Kasei
•
pH7 Technologies Raises $32M in Series B FundingFinSMEs•Apr 13, 2026•PH7Technologies, Fine Structure Ventures, Circular Innovation Fund, BHP and 4 others
•
Pritelivir Shows Superior Efficacy in HIV Patients with HSV in Phase 3GlobeNewswire•Feb 26, 2026•AiCuris
•
Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 millionChemengonline•Feb 26, 2026•Asahi Kasei, AiCuris, http://asahikasei.com
•
AiCuris Announces Pritelivir Phase 3 HSV Data Presentation at TandemGlobeNewswire•Jan 29, 2026•AiCuris
•
Smartbax licenses compound from Aicuris for next-generation antibiotic developmentPMLiVE•Jan 20, 2026•smartbax, AiCuris
•
Aicuris Presents Pritelivir Phase 2 Results and AIC468 Phase 1 Safety Data at ID Week 2025GlobeNewswire•Oct 20, 2025•AiCuris
•
•
AiCuris Announces Upcoming Oral and Poster Presentations at ID Week 2025GlobeNewswire•Sep 16, 2025•AiCuris
Are you a Founder ?
FAQs about AiCuris
Explore our recently published companies
- DIV Protocol - Paris based, 2025 founded, Unfunded company
- D and H Fire - San Dimas based, 2016 founded, Funding Raised company
- Eye7 Eye Hospitals - Delhi based, 1987 founded, Unfunded company
- AiLuvio - Praha based, 2023 founded, Unfunded company
- Receptive Sports Technologies - Ludhiana based, 2022 founded, Unfunded company
- Goods For Health - Delhi based, 2025 founded, Unfunded company
